Featured Press Releases

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene’s Detalimogene Receives RMAT Designation from the FDA, Opening the Path for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

  • 25 Jun 2025

enGene Holdings Inc. a clinical-stage, non-viral gene-based immunotherapy company, announced that...

Prendio-BioProcure presents PrendioPay, simplifying procurement for life science companie

Prendio-BioProcure presents PrendioPay, simplifying procurement for life science companie

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Avanzanite forms a Pan-European partnership with Agios to introduce PYRUKYND® for rare blood disorders

Avanzanite forms a Pan-European partnership with Agios to introduce PYRUKYND® for rare blood disorders

Prestigious Journal of Hematology & Oncology Accepts HanchorBio’s Novel CD47-SIRPα Therapeutic, HCB101, for Publication

Prestigious Journal of Hematology & Oncology Accepts HanchorBio’s Novel CD47-SIRPα Therapeutic, HCB101, for Publication

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

  • Jazz Pharmaceuticals plc
  • 17 Nov 2025
New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

  • Johnson & Johnson
  • 17 Nov 2025
Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

  • Asahi Kasei
  • 13 Nov 2025
Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

  • Odyssey Therapeutics, Inc.
  • 11 Nov 2025
HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

  • HanchorBio Inc.
  • 10 Nov 2025

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.